Pioneering the Next Generation of Neuropsychiatric Medicines
Küleon is a drug discovery and development company leveraging proprietary, AI-based technology to identify novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders.
Our Science
Küleon develops small molecule therapeutics for neuropsychiatric conditions that can be modulated through serotonin receptors found in the prefrontal cortex of the brain. Selective modulation of certain serotonin receptor subtypes can be leveraged to treat a variety of diseases and disorders, including addiction (to alcohol, cocaine, nicotine, methamphetamines, and more), schizophrenia, obesity, pain, inflammation, and neurodegeneration.
Get in Touch
We are passionate about our mission to bring better treatments to serious neuropsychiatric diseases and disorders, and welcome you to reach out. From investing in Küleon to academic collaborations and open job applications, we are happy to explore potential ways to collaborate with you. Click the “Contact Us” button to get in touch with us.
